Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs

Background Orphan drugs offer important therapeutic options to patients suffering from rare conditions, but are typically considerably more expensive than non-orphan drugs, leading to questions about their cost-effectiveness. Objective To compare the value of orphan and non-orphan drugs approved by...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of general internal medicine : JGIM 2020-09, Vol.35 (9), p.2629-2636
Hauptverfasser:	Chambers, James D., Silver, Madison C., Berklein, Flora C., Cohen, Joshua T., Neumann, Peter J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cost analysis Cost-Benefit Analysis Costs Drug development Drugs Humans Indication Internal Medicine Medicine Medicine & Public Health Original Research Orphan Drug Production Pharmaceutical industry Quality-Adjusted Life Years
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!